Emerging evidence on oral contraceptives and arterial disease

A number of case-control studies published in recent years have shown an apparent increase in the risk of venous thromboembolism (VTE) associated with the use of third-generation oral contraceptives (OCs) compared with second-generation OCs. However, it is thought that these studies were subject to...

Full description

Saved in:
Bibliographic Details
Published in:Contraception (Stoneham) 2000-08, Vol.62 (2), p.S29-S36
Main Author: Heinemann, Lothar A.J
Format: Article
Language:English
Subjects:
Adult
Bias
Biological and medical sciences
Contraceptives, Oral - adverse effects
Drug toxicity and drugs side effects treatment
Female
Humans
Medical sciences
Middle Aged
Myocardial infarction
Myocardial Infarction - epidemiology
Myocardial Infarction - etiology
Oral contraceptives
Pharmacology. Drug treatments
Risk Factors
Stroke
Stroke - epidemiology
Stroke - etiology
Toxicity: cardiovascular system
Vascular Diseases - etiology
Venous thromboembolism
Venous Thrombosis - epidemiology
Venous Thrombosis - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A number of case-control studies published in recent years have shown an apparent increase in the risk of venous thromboembolism (VTE) associated with the use of third-generation oral contraceptives (OCs) compared with second-generation OCs. However, it is thought that these studies were subject to a number of biases that would have increased the risk estimates for third-generation OCs while lowering those for second-generation preparations. Data on the risk of ischemic stroke and myocardial infarction (MI) show no such difference between generations of OCs, with a statistically significant reduction in the risk of acute MI from first- to third-generation in one major study. Available results indicate that there is no significant increase in the risk of ischemic stroke or acute MI associated with the use of low-dose estrogen OCs in young women who are properly screened before use, and who have no pre-existing cardiovascular risk factors, such as smoking and hypertension, for these conditions. These findings should be taken into account when interpreting the results of studies on the risk of VTE in women taking combined OCs.
ISSN:0010-7824
1879-0518
DOI:10.1016/S0010-7824(00)00146-3